These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38425268)

  • 1. Managing pediatric-onset multiple sclerosis in an austere setting: A case report.
    Pierce Pucci JU; Soloria HM; Eye PG
    J Telemed Telecare; 2024 Feb; ():1357633X241235701. PubMed ID: 38425268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term fingolimod treatment in two pediatric patients with multiple sclerosis.
    Borriello G; Pozzilli C
    Neurol Sci; 2021 May; 42(Suppl 1):29-36. PubMed ID: 33751260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of fingolimod after switching from interferon β-1a in an adolescent with multiple sclerosis: case report.
    Amidei A; Siciliano G; Pasquali L
    Neurol Sci; 2021 May; 42(Suppl 1):5-7. PubMed ID: 33723709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teleneurology.
    Patterson V
    J Telemed Telecare; 2005; 11(2):55-9. PubMed ID: 15829048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demographic Features and Clinical Course of Patients With Pediatric-Onset Multiple Sclerosis on Newer Disease-Modifying Treatments.
    Malani Shukla N; Casper TC; Ness J; Wheeler Y; Chitnis T; Lotze T; Gorman M; Benson L; Weinstock-Guttmann B; Aaen G; Rodriguez M; Tillema JM; Krupp L; Schreiner T; Mar S; Goyal M; Rensel M; Abrams A; Rose J; Waltz M; Liu T; Manlius C; Waubant E;
    Pediatr Neurol; 2023 Aug; 145():125-131. PubMed ID: 37348193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple sclerosis in a 4-year-old boy: a case report and literature review.
    Arkar U; Vipotnik Vesnaver T; Osredkar D; Perković Benedik M; Bizjak N
    Front Neurol; 2024; 15():1359938. PubMed ID: 38585366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment.
    Jakimovski D; Awan S; Eckert SP; Farooq O; Weinstock-Guttman B
    CNS Drugs; 2022 Jan; 36(1):45-59. PubMed ID: 34940954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset multiple sclerosis: focus on immunological data.
    Gontika M; Skarlis C; Markoglou N; Evangelopoulos ME; Velonakis G; Chrousos GP; Dalakas M; Stefanis L; Anagnostouli M
    Neurol Sci; 2022 Apr; 43(4):2641-2649. PubMed ID: 34596776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fingolimod as first-line treatment in pediatric-onset multiple sclerosis: a case report.
    Capobianco M; Bertolotto A; Malucchi S
    Neurol Sci; 2021 May; 42(Suppl 1):25-28. PubMed ID: 33712907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telemedicine for the Medicare population: pediatric, obstetric, and clinician-indirect home interventions.
    Hersh WR; Wallace JA; Patterson PK; Shapiro SE; Kraemer DF; Eilers GM; Chan BK; Greenlick MR; Helfand M
    Evid Rep Technol Assess (Summ); 2001 Aug; (24 Suppl):1-32. PubMed ID: 11569328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What an adult multiple sclerosis registry can tell us about pediatric onset multiple sclerosis?
    Alkolfat F; Said S; Mekky J; Eldeeb H
    Mult Scler Relat Disord; 2023 Nov; 79():104962. PubMed ID: 37714097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis.
    Macaron G; Feng J; Moodley M; Rensel M
    Curr Treat Options Neurol; 2019 Sep; 21(10):50. PubMed ID: 31560095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fingolimod in pediatric multiple sclerosis: three case reports.
    Ferilli MAN; Papetti L; Valeriani M
    Neurol Sci; 2021 May; 42(Suppl 1):19-23. PubMed ID: 33483884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on pediatric-onset multiple sclerosis.
    Ruet A
    Rev Neurol (Paris); 2018 Jun; 174(6):398-407. PubMed ID: 29784250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review Of The Safety, Efficacy And Tolerability Of Fingolimod In The Treatment Of Pediatric Patients With Relapsing-Remitting Forms Of Multiple Sclerosis (RRMS).
    Feng J; Rensel M
    Pediatric Health Med Ther; 2019; 10():141-146. PubMed ID: 31814792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newer disease modifying treatments in pediatric onset multiple sclerosis: Experience from a single center.
    Solmaz I; Acar Ozen P; Parlak S; Tuncer A; Anlar B
    Eur J Paediatr Neurol; 2022 Jul; 39():110-115. PubMed ID: 35777190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric Multiple Sclerosis-Experience of a Tertiary Care Center.
    Martins C; Samões R; Silva AM; Santos E; Figueiroa S
    Neuropediatrics; 2023 Feb; 54(1):58-63. PubMed ID: 36646103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of clinically isolated syndrome to pediatric-onset multiple sclerosis and a review of the literature.
    Solmaz İ; Öncel İ
    Turk J Med Sci; 2022 Aug; 52(4):1281-1287. PubMed ID: 36326415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric Multiple Sclerosis: an Update.
    Otallah S; Banwell B
    Curr Neurol Neurosci Rep; 2018 Sep; 18(11):76. PubMed ID: 30229541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of fingolimod versus interferon-β1a for the treatment of pediatric-onset multiple sclerosis in Canada.
    Nakhaipour HR; Vudumula U; Khurana V; Sébire G; Mah JK; Pohl D; Schecter R; Adlard N
    J Med Econ; 2020 Dec; 23(12):1525-1533. PubMed ID: 33079578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.